Blog
Peace in strength. Like the mighty oak that has survived some 600 years in what is now my back yard, we engage with experience and resilience. Whether the winds blow hard or the sun shines bright, we go on, deeply rooted and stretching for the heavens.
Strength in peace. Many challenges of the world, and Pharmaceutical R&D, grow out of mere misunderstandings. We seek to enhance mutual understanding and peaceful cooperation toward shared objectives.
- Peace and Strength by Kevin Freiert
The last few years have been hard. Hard for humans, and equally as hard for a business that just started to feel growth before COVID put projects, funding, and plans at a standstill. 2022 felt like a new beginning. We were able to travel again to see so many familiar…
Read More
Dr. Stephen Hahn, Commissioner of the FDA has stated that the FDA will be able to grant Emergency Use Authorization before the end of the Phase 3 Trials. That is absolutely true but the ends of the Phase 3 Trials are in 2022.
The real question is,
“When is the earliest that an Emergency Use Authorization could legitimately be announced?”
FOR IMMEDIATE RELEASE Contact: Heather McCullen, Salem Oaks LLC Phone: 518.791.8812 Email: heathermccullen@salemoaks.com Salem Oaks and The Friedreich’s Ataxia Research Alliance Are Partnering on Course on Clinical Trial Protocols January 3, 2020—Salem Oaks, LLC and The Friedreich’s Ataxia Research Alliance (FARA) are excited to announce a partnership to offer a new learning opportunity…
Read More
Writing goals and expectations at the beginning of each year is a double-edged sword. On one hand, it is critical to provide some semblance of focus in the midst of all the activity around us. On the other, when looking back we see just how uninformed we were. Like trees,…
Read More
She encouraged each of us to find our crack in the expansive ice of rare disease and drive a wedge into it. The effort of everyone continually working their own little crack (science, policy, direct experience, economics, medicine, fundraising, advocacy, or whatever) will eventually weaken the ice enough to shatter it. Together we can beat these diseases. This got me thinking about the contribution of Salem Oaks.
Read More
Meet Kyle Bryant On our next episode of Improbable Developments we welcome Kyle Bryant of the Friedreich’s Ataxia Research Alliance (FARA) to discuss his journey as a patient with Friedreich’s Ataxia (FA), as an active patient leader, and in his job as a liaison between the FA community and researchers.…
Read More
Our experience at Global Genes Rare Patient Summit I think what needs to be pointed out in that title, is the word RARE. This conference is anything but ordinary. The attendees are amazing and consist of a diverse population of patients, experts, consultants, and advocates who are all teaming together…
Read More
Right now, you are alone. When a college student arrives on campus for their first day of freshman year, they are typically alone. They haven’t yet found a close friend, they haven’t started classes yet to meet anyone, and their roommate is more than likely a stranger. They are a…
Read More
I don’t know how this happens. I haven’t been formally in school for 25 years, but my calendar seems totally unable to shake the habit of “getting ready” for the next academic year. And the same seems to be true for Salem Oaks! We have so much planned for…
Read More
The science of drug discovery and development creates a rich landscape for all sorts of stories to unfold.
Each month we are going to talk to someone who was in the trenches of R&D and let them tell their story. We’ll be talking about medicines you may know and some that never saw the light of day.
Read More